title: A shift from demerol (meperidine) to dilaudid (hydromorphone) improves pain control and decreases admissions for patients in sickle cell crisis.
authors.affiliation: Emergency Department, Presbyterian Hospital of Dallas, Dallas, TX, USA. Kmp63052@aol.com
authors.forename: Kathryn M
authors.initials: KM
authors.lastname: Perlman
authors.forename: Suzanne
authors.initials: S
authors.lastname: Myers-Phariss
authors.forename: Jeremy C
authors.initials: JC
authors.lastname: Rhodes
mesh_terms: D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D002985:Clinical Protocols; D004636:Emergency Service, Hospital / Q000458:organization & administration*; D006801:Humans; D004091:Hydromorphone / Q000008:administration & dosage*; D008614:Meperidine / Q000008:administration & dosage*; D010146:Pain / Q000517:prevention & control*; D010147:Pain Measurement; D010343:Patient Admission / Q000706:statistics & numerical data; D015397:Program Evaluation
chemical_list: D008614:Meperidine; D004091:Hydromorphone